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Polyphosphazenes (PPZs) are a relatively new family of polymers based on a nitrogen-
phosphorous backbone where organic side-groups can be grafted.  The synthetic route to PPZs 
is highly versatile such that it is possible to add many different functionalities that change 
completely the physicochemical and biological properties of the polymers. For instance, PPZs 
can be designed with a variety of organic side groups that render these materials biodegradable 
and highly biocompatible. Based on these positive features, PPZs have been explored for many 
biomedical applications including the design of numerous advanced drug delivery systems. In 
this area, PPZs have been particularly investigated as materials for the formulation of 
biopharmaceuticals of high added value. These include protein- and polynucleotide-based 
medicines, applications where PPZ carriers have obtained very positive results in pre-clinical 
models. A further area of major interest for PPZs has been vaccination, where these materials 





Part I. Background and fundamental properties of PPZ 
New biodegradable materials are required in many biomedical applications, and polymers 
continue to be critical for this field. In comparison to natural polymers, synthetic biodegradable 
polymers are generally better defined and are easier to modulate regarding their mechanical and 
degradation properties. Polyesters such as polylactide (PLA), poly(lactide-co-glycolide) 
(PLGA), or polycaprolactone (PCL) are some of the most used synthetic polymers, but other 
polymer families such as polyphosphazenes (PPZs) are also of interest since they bring 
advantages of tunable biodegradability, polymer elasticity and chemical versatility. Due to 
these characteristics, polyphosphazenes are being investigated in a range of biomedical 
applications such as controlled drug delivery and tissue engineering1,2.  
Polyphosphazenes (PPZs) are a class of polymers having an inorganic backbone made of 
repeating units of phosphorus and nitrogen in an alternating sequence, and which can be 
configured in cyclic or linear conformations. The repeating unit of PPZs is N=PR1R2 (Figure 
1a), a structure built by phosphorus covalently linked to nitrogen via alternating σ-σ bond and 
σ-π bonds. Each phosphorus atom offers five electrons and each nitrogen provides another five 
electrons, forming sequential saturated and unsaturated bonds on the backbones. Within this 
structure two electrons of the phosphorus are used for side chain conjugation, and two electrons 
of nitrogen remained as a lone-pair (Figure 1b). Although the linear backbone contains 
unsaturated bonds, the dπ(P)−pπ(N) bond is expected to have flexible rotation because several 
3d orbitals of phosphorus can hybridise with the pz orbital of nitrogen once the π bond 
undergoes torsions (Figure 1c) 3,4. As theoretical calculations report, the bond energy of 
inherent torsional barrier in the phosphazene backbone is as low as 100 cal per bond 4,5. 
Nevertheless, the linear PPZ conformation is significantly influenced by their side groups (i.e. 
Cl, OCH2CF3, etc.), since the phosphazene skeleton is easily distorted and lies preferably in a 
cis-trans rather than in a trans-trans planar conformation to minimize internal repulsions 
(Figure 1d) 3,6. Because of the flexible dπ(P)−pπ(N) bond, most PPZ are colorless, have 
insulating properties and lack microcrystallinity. This is more apparent in PPZs having two or 
more different substituting side groups 4.  
The most commonly prepared PPZ is poly(dichlorophosphazene) (PDCP), which is synthesized 
as a precursor for its derivation to a wide range of polymers by nucleophilic substitution 7.  
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Many PDCP derivatives have been synthesized and formulated to various products in 
biomedical applications. For example, amino acid ester PPZs have been widely studied and 
applied to prepare fibers or scaffolds by electrospinning for bone tissue engineering 8,9; 
amphiphilic PPZs have been used for the preparation of nanoscale polymeric carriers in 
controlled drug delivery 10,11. For vaccine delivery the most common prototypes are based on 
PPZs with carboxylic acids side chains, such as poly[di(carboxylatophenoxy)-phosphazene] 
(PCPP). The versatility of PPZ chemistry is also important from scale-up and manufacture 
perspectives 12-14. For many industrial applications, it is desirable to have ‘platform’ materials 
that can be manufactured in bulk and adapted or modified for specific purposes. For 
pharmaceutical applications, a single precursor polymer that can be tailored for different 
therapies would be highly advantageous. In this review we focus on linear PDCP derivatives 
and their bio-applications in gene delivery, vaccine delivery and protein drug delivery. 
 
 
Figure 1. General structures of PPZ (a), electron arrangement in the phosphazene bond (b) and 
its orbital hybridization (c), in which phosphorus provides dxz to hybrid with pz of nitrogen. (d) 




Synthesis of polyphosphazene and functional additions 
The first synthesis of PPZ was reported by Stokes as early as 1897 in a high-temperature 
polymerization reaction that led into an insoluble elastomer known as inorganic rubber. The 
first stable synthesis of PPZ was reported by Allcock and co-workers 15, a work that resulted in 
increased interest for these kind of materials for biomedical and other applications. The scheme 
developed by Allcock is still the basis of the most general procedure for linear PPZ synthesis: 
the precursor poly(dichlorophosphazene) (PDCP) is prepared in the first step, and then the final 
polymer is formed by nucleophilic substitution of the desired side chains 1,16,17.  
Based on the raw monomers used to prepare linear PDCP, synthetic methods can generally be 
classified based on those starting from cyclic trimers (i.e. hexachlorocyclotriphosphazene, 
(NPCl2)3) 15,18, and those starting from non-cyclic monomers (i.e. dichlorophosphinoyl-
iminotrichloro phosphorene, Cl3P=N-P(O)Cl2, or trichloro(trimethylsilyl)phosphoranimine, 
Cl3P=NSiMe3) 19-22. In the former case, the polymerization is typically thermo-initiated and the 
ring-opening reaction propagates towards linear PDCP (Figure 2a). Many aspects of this 
general PDCP synthesis procedure have been improved, including catalyzed polymerization 
23,24 and solvent-mediated stabilization25. Although the mechanism of this ring-opening 
polymerization is still open to debate, the most broadly accepted mechanism is that one 
phosphorus-chloride bond of the cyclic trimer is cleaved by heating above 250 - 260 ºC, 
triggering the opening of the next cyclotriphosphazene and starting the chain propagation 
reaction. In the terminal step, the reactive head of the PPZ chain (~N=PCl2+) can recapture the 
chloride anion as the reaction temperature decreases. This reaction is extremely sensitive to 
contamination by water and other nucleophiles, which can cause unwanted cross-linking, and 
precipitation of an insoluble material (i.e. Stokes’ “inorganic rubber”) as well as limiting the 
reproducibility of the synthesis. For avoiding water contamination, a solvent-free melt 
polymerization reaction can be used, but this reaction is difficult to control and forms ultra-high 
molecular weight PDCP.  
The use of efficient catalysts is a critical factor to achieve high-yield, controllable 
polymerization of PDCP and to obtain a product with sufficient purity to proceed for side 
change substitution reactions without further purification 23,24. Boron trichloride (BCl3) and 
aluminum chloride (AlCl3) are strong Lewis acids that facilitate the extraction of the chloride 
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on the trimers and act as catalysts for cyclic trimer activation. BCl3 has the additional 
advantage of reducing the possibility of crosslinking by eliminating trace amounts of water in 
the polymerization by forming B(OH)3 23. Sohn et al. also reported that AlCl3 can be used as a 
catalyst in PPZ polymerization to yield PDCP with a mass average molecular weight (Mw) 
range between 10kDa and 100k Da 24, which is preferred for many biomedical applications, 
especially drug delivery and tissue engineering 26,27.  
Besides these methods relying on ring-opening polymerization starting from 
hexachlorocyclotriphosphazene, PDCP can also be synthesized through phosphorus 
pentachloride (PCl5) initiated polymerization starting from non-cyclic monomers, such as 
trichloro(trimethylsilyl)phosphoranimine, Cl3P=N-Si(CH3)3 (Figure 2b) 19,20,22. This method 
has several advantages such as room-temperature synthesis and controllable molecular weights 
with narrow polydispersity. Most interestingly, this polymerization method can be used to 
prepare further block copolymers, such as PLA-co-PDCP, PEO-co-PDCP and polystyrene-co-
PDCP 28-30. The first section of polymer with terminal primary amines can conjugate with 
(CF3CH2O)2BrP=NSiMe3 by nucleophilic substitution and then react with PCl5 to initiate the 
polymerization of the PDCP block. In light of this, PCl5-induced living cationic polymerization 
provides broader possibilities for PPZ platforms, such as the preparation of amphiphilic 





Figure 2. Potential mechanisms for PPZ polymerization. (a) Ring-opening polymerization of 
cyclotriphosphazene and (b) living cationic polymerization of 
trichloro(trimethylsilyl)phosphoranimine to yield linear poly(dichlorophosphazene)s (PDCP).  
 
Despite all the work on improving its synthesis, PDCP has few applications itself, but rather 
acts as a  precursor polymer that, to date, has been modified into over 700 different derivatives 
4,7. Indeed, PDCP provides an easy-coupling platform for conjugation with side-chain 
candidates, in which nucleophile terminals can substitute the chlorines of this polymer, 
effectively conjugating to the PPZ backbone. Despite the flexibility of this reaction, the 
nucleophilic substitution is limited to functional groups having only one nucleophilic center. If 
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groups having more than one nucleophilic center are used, a crosslinking reaction and the 
precipitation of the polymer intermediate will result. Therefore, many functional groups of 
biological interest (amines, acids, or saccharide molecules etc.) need to go through 
protection/deprotection procedures for their nucleophilic substitution on PDCP. Fortunately, an 
extensive library of PPZs has been developed, including derivatives substituted with alkene, 
alkyne, or vinyl groups, for example, allylamine 14,31, 2-aminoethyl methacrylate 32, allyl 
glycinate 33, methacrylic acid 34,35 and propargylamine 36 derivatives. These PPZs with alkene 
and alkyne side chains can be used as secondary precursors for free radical polymerization 
32,33,35,37. Furthermore, recent works have shown the possibility to use these groups in thiol-ene, 
thiol-yne and azide/alkyne click reactions as simple pathways for PPZ derivatization with 
biomolecules 14,36,38,39. These reactions have also been applied as simple schemes to add ionic 
side chains on the PPZ backbone for the design of gene therapy polymers 40. Overall, free-
radical polymerization and click reactions bring additional versatility to PPZs and allow for the 
introduction of potential biomolecules or therapeutic compounds as side chains. 
 
Biocompatibility and Biodegradability of polyphosphazenes 
Poly(organophosphazenes) is a term for PPZs having organic side groups. These polymers 
cover a broad range of materials with tunable cytocompatibility and biodegradability 7,41, and 
thus the following discussion is centered on these PPZs. A considerable number of organic side 
chains have been introduced in PPZs, including amino acid esters 7,42-44, peptides 33,42,45, 
saccharides 14,36,46, arylcarboxylates 47, ethylene oxide/PEG 11,27,48, and other biomolecules 
(purine and pyrimidine bases, vitamins, etc.) 49,50. For biomedical applications, the safety of 
these materials is a key consideration. As with other properties of polyphosphazenes, the 
cytocompatibility of the final materials is dictated by the side groups used. For instance, 
polyphosphazenes substituted with tertiary amines can exert certain toxicity even at moderate 
concentrations 51. On the other hand, other polyphosphazenes used in bone tissue engineering 
show excellent safety profiles 9. For instance, poly[(ethyl glycinato) phosphazene] has been 
compared to PLGA in a cytocompatibility test performed in primary rat osteoblasts, where this 
PPZ showed no negative effect on cell proliferation 52. This study also inspired further tests of 
alanine-based PPZs regarding osteocompatibility. This material showed low toxicity and good 
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capacity to support cell adhesion, proliferation, and maintenance of cellular phenotype 53,54. 
Other types of PEGylated PPZs also show excellent biosafety profiles that combine with their 
antifouling properties 55-57. The biocompatibility of the PPZ backbone has also been supported 
by the FDA-approval of Cobra PzF stents (CeloNova Biosciences Inc.) in 2017, which are 
coronary stents coated with nanostructured PPZs for thrombo-resistant properties 58. 
A critical characteristic of poly(organophosphazenes) is their capacity to biodegrade, which is 
beneficial in many medical applications. The mechanism for hydrolysis of these PPZs is still 
controversial and three possible mechanisms have been suggested 41,59,60. In mechanisms 1 and 
2 (see Figure 3), the side groups can react with the phosphazene backbone and accelerate 
polymer hydrolysis. In the other mechanism, the side chains of PPZs may be eliminated from 
their backbone first, and finally the backbone can be hydrolyzed. In all cases, the result of the 
hydrolysis is the formation of degradation products from the side groups and a self-neutralizing 
buffer of ammonium phosphate derived from the backbone 7,43. The neutrality of these 
degradation products is another advantage over other biodegradable polymers that form acid 
residues that can harm delicate biomolecules 61,62. 
The degradation rate of PPZs is also dependent on the substituting side groups and their ratios 
when there is more than one type 63. Within this regard, important characteristics of the side 
groups are: hydrophobicity, steric hindrance, and the degree of crosslinking of the side chains. 
The lack of systematic studies has made it difficult to compare a broad range of side chains 
under standardized conditions 7. However, some amino-acid ester PPZs have been studied in 
detail by the group of Allcock, where they calculated their degradation half-life (T1/2) in PBS 
37 ºC as follows: ethyl glycinate (T1/2 ~3 months) < alanine (T1/2 ~6 months) < valine (T1/2 ~ 1 
year) ≦ phenylalanine ethyl ester (T1/2 ~1 year) 43,44,64. Moreover, when analyzing two water-
soluble PPZs with the same terminal functional side group (i.e. a tertiary amine), but linked to 
the PPZ backbone by a different nucleophile group, –N=P(–OCH2CH2N(CH3)2)2 vs. –N=P(–
NHCH2CH2N(CH3)2)2, the authors found that the alkoxide-substituted PPZ degraded faster 
(T1/2 ~7 days) than the amine-substituted PPZ (T1/2 ~24 days) 51.  
In conclusion, the good cytocompatibility profile of poly(organophosphazene)s together with 
their biodegradation kinetics that can be tuned by selecting appropriate side groups is another 
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positive characteristics that indicates the interest of these materials for tissue engineering and 
drug delivery 9,41,65,66.  
 
Figure 3. The three common hypotheses of poly(amino-acid ester)phosphazenes for 







Part II. Use of PPZs for the delivery of biomacromolecules 
Macromolecular drugs (polysaccharides, protein, nucleotide, etc.) are increasingly important in 
the clinical arsenal and are likely to be the main class of therapeutics in many future disease 
treatments.  However, most biomacromolecules have low stability in the body and lack the 
capacity to cross biological barriers. New carriers to improve the delivery of macromolecules 
are thus urgently needed. PPZ-based platforms combine chemical flexibility, biodegradability 
and biocompatibility, suitable characteristics that suggest their use for macromolecule carrier 
design. Here we review the use of PPZ platforms for gene and protein delivery; afterwards, we 
cover specifically the use of PPZs for protein and gene delivery in vaccination, since this 
application has particular technical requirements. 
 
Gene delivery 
Gene therapies are some of the most promising advanced treatments under investigation today, 
and they have already resulted in some new medicines translated to the clinic.  The major 
bottleneck towards the successful use of DNA and RNA is their delivery to the target tissues as 
well as to their target cell compartments. This delivery problem results in poor efficacy/toxicity 
ratios and has slowed the development of gene therapy for decades 67-69. In polymer-mediated 
gene delivery, the most widely-investigated material is polyethylenimine (PEI), whose 
positively charged amine groups can condense polynucleotides leading to the formation of 
nanocomplexes. PEI-nucleotide polyelectrolyte complexes can be taken up by cells and the 
buffering capacity of the PEI backbone amines can facilitate their escape from endosomal 
compartments, effectively improving the intracellular delivery of the gene medicines 70. 
However, PEI has important limitations regarding its medical use: it is non-biodegradable and 
has detrimental effects related to mitochondrial dysfunction 71-73, thus better alternative 
polymers are sought as gene delivery carriers. 
The first PPZ employed for the purpose of gene delivery was reported by Hennink's group 51, 
who compared the degradation ratios of two terminal tertiary amines as PPZ side chains, 2-
dimethylaminoethanol (DMAE) and 2-dimethylaminoethylamine (DMAEA). The 
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corresponding cationic polymers were used to complex plasmid DNA for gene delivery 
(Figure 4). The studies indicated that DMAEA-PPZ complexing DNA has higher gene transfer 
efficiency than DMAE-PPZ in the COS-7 cell-line, especially at low N/P ratios ≤ 10 (the molar 
ratio of pronated amine group to negative phosphate of nucleotide). However, DMAEA-PPZ 
has higher toxicity than DMAE-PPZ at high N/P ratios (≥ 20), likely due to the short half-life 
of DMEA-PPZ. Besides, these authors also investigated the effect of DMAEA-PPZs molecular 
weight on DNA delivery efficiency. The lower molecular-weight polymers (Mw range of 130-
950k Da) resulted in acceptable toxicity both in vitro and in vivo 74.  Further improvements in 
these early prototypes were achieved by introducing imidazole groups in DMAEA-PPZs as 
added functionalities to improve endosomal escape and enhance transfection efficiency 75,76. 
Other chemical modifications of PPZ included grafting with galactose 77 and PEG 78 to improve 
biocompatibility and stability of the drug carriers.  
These initial designs were mostly limited to grafting PPZs with groups having only one 
nucleophilic center due to synthetic limitations related to uncontrolled polymer crosslinking 
that could only be avoided by cumbersome protection/de-protection procedures 79-81. For 
addressing this issue, Hsu et al. used a click-addition extension starting from a PPZ backbone 
(Figure 4) and applied this synthetic strategy to the design of a small library of materials for 
gene delivery that included previously unexplored primary amine PPZs and carboxylic acid 
PPZs of medium/low molecular weight ranges (10 kDa to 50 kDa) 40. Primary amine PPZs 
were found to be more efficient for gene delivery than tertiary amine PPZs due to their higher 
binding capacity for DNA. Additionally, the authors identified a carboxylic acid functional 
grafting group that could be added to the gene nanocarriers as a delivery enhancer. This 
material not only reduced the toxicity on the nanocarriers, but improved gene transfection in 
several 2D and 3D cell models, as well as in vivo. In perspective, cationic PPZ-based gene 
complexes show comparable gene delivery efficacy to commercial standards (PEI or 
Lipofectamine), but they tend to show lower cytotoxicity and have the additional advantage of 
being biodegradable 40,57,76,78,82.  
Standard polyelectrolyte complexes are not the only type of structures that have been tested for 
gene delivery. For instance, thermosensitive, injectable PPZ gels have been used for the 
controlled release of chitosan-graft PEI/DNA complexes or PEI-grafted PPZ/DNA complexes 
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83. This type of system can be used for local administration to achieve sustained release of the 
polymer/gene complexes 84,85. Other types of structures of interest are polymersomes and 
polymeric micelles. Qiu’s group developed PEG-PPZ block copolymers where PPZs were 
substituted with hydrophobic N,N-diisopropylethylenediamine (DPA) groups. The copolymers 
were amphiphilic and could be formulated as polymersomes. When these polymersomes were 
loaded with microRNA (miR-200c), the nanomedicine was capable of inhibiting tumor 
progression in xenografted mice with a drug-resistant lung cancer model 57. Polymersomes 
were also used to deliver plasmids coding for recombinant IL-12, a protein that can activate 
cytotoxic T lymphocytes and natural killer cells in antitumor immunotherapy, but which can 
also present severe side effects via standard intravenous administration 86,87. The polymersome 
was able to deliver the plasmid to CT-26 tumors in mice upon intravenous administration. This 
delivery system prolonged the half-life of IL-12 in the tumor region and in serum, while they 
minimized the therapy adverse effects 88. After the polymersome treatment, immune effector 
cells (CD8+ T cells, NK cells and NKT cells) were recruited in the tumor environment, and 
increased concentrations of IFN-γ shortly after the treatment. 
 
Figure 4. The common techniques to introduce cationic side chains on polyphosphazene (PPZ) 




Protein drug delivery 
The possibility of generating materials with tailored degradation kinetics and their amenability 
to easily integrate other functionalities make poly(organophosphazene)s an attractive choice for 
protein delivery. Based on their general structure, we highlight two main strategies that have 
been followed in PPZ-based protein formulation: (i) nanoparticles and (ii) injectable gels. 
Nanoparticles can be designed to provide protein stabilization and improved intracellular 
trafficking. For instance, the group of Andrianov presented an ionic polyphosphazene for 
“smart” protein delivery 89. In this work, poly(carboxylatoethylphenoxy)-co-(3-(2-oxo-1-
pyrrolidinyl)-propylamino)phosphazene, PPA was designed with degradable/pH-sensitive 
functions. The optimized composition of PPA can induce hemolysis at endosomal pH, 
facilitating endosomal escape after internalization in cancer cells. Carboxylatoethylphenoxy 
(CEP) side chains are well-known for their use in complexation with proteins, but they are also 
sensitive to changes in pH within the physiological range. Complexation of L-Asparaginase 
with both negatively-charged CEP-grafted and positively-charged tertiary amine-grafted PEG-
PPZ derivatives can form non-covalent PEGylated nanoassemblies for protein delivery; these 
nanocarriers promoted the stability of this enzyme and reduced their undesirable antigenicity 55.   
Since the short in vivo half-life of proteins is one of their most frequent shortcomings, 
injectable controlled release formulations are in great need. Non-ionic, thermosensitive PPZ 
polymers that gel at body temperature and provide sustained delivery of proteins are very 
promising in this regard. For instance, this type of hydrogel can be generated with PPZs grafted 
with three side chains corresponding to different functions: the hydrophobic L-isoleucine ethyl 
ester (IleOEt), the hydrophilic α-amino-ω-methoxy-poly(ethylene glycol) (AMPEG), and the 
hydrolysis-sensitive ethyl-2-(O-glycyl)lactate (GlyLacOEt). In this design, the ratio between 
IleOEt and AMPEG side groups define the lower critical solution temperature behavior (LCST), 
and thus the body temperature where the polymer will gel. GlyLacOEt moieties facilitate acid-
catalyzed degradation and controlled protein drug release 27,90. A composition of this polymer 
family capable of gelling at body temperature upon injection was used to formulate human 
growth hormone (hGH). This formulation formed a depot with sustained release properties that 
could address clinical issues associated with hGH treatments, such as renal toxicity and short 
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half-life, which otherwise require multiple-injections leading to poor patient compliance 91. 
Unfortunately, direct loading of hGH in this PPZ hydrogel still results in a large burst and fast 
release rates, which result in total cargo release in 1 week or less 92,93. To improve this result, 
hGH was complexed with poly-L-arginine, and these biodegradable nanocomplexes then were 
loaded in the thermosensitive PPZ hydrogel. This multi-stage formulation could significantly 
prolong the release phase for several weeks. In another work, PPZs were designed to have dual 
interactions with proteins in order to generate more stable release profiles. The PPZs were 
grafted with hydrophilic PEG, hydrophobic isoleucine ethyl ester (IleOEt) and carboxylic acid 
moieties that could complex BMP-2 and form stable nanocomplexes.  Compared to non-
anionic amphiphilic PPZs complexes, anionic BMP-2 nanocarriers were able to duplicate the 
duration of BMP-2 release and avoid the burst effect. This formulation achieved continuous 
BMP-2 stimulation in vivo and resulted in osteocalcin secretion even two weeks after a single-
dose injection of this nanocomplex. The treatment demonstrated new bone generation on 
mouse ectopic and orthotopic sites after 8 weeks 94. 
 
Vaccine delivery 
Vaccination is currently the most cost-effective method for protection against infectious 
diseases. Generally, vaccines are derived from either live attenuated pathogens, killed antigens 
or their sub-units 95. Vaccines based on whole pathogens are usually highly immunogenic but 
present safety concerns which often limit their use in high-risk populations (eg. pregnant 
women, elderly etc.). Recently developed vaccine (i.e. subunits, recombinant antigens, 
nucleotide, surface saccharides, etc.) are safer but typically generate weak immune responses. 
In light of this, such antigens generally require the use of  adjuvants, which could improve both 
the delivery of the antigen and its immunostimulatory properties 96. This concept of immune 
adjuvants was originally proposed by Gaston Ramon 97, as “substances used in combination 
with a specific antigen that produce a more robust immune response than the antigen alone.” 
The most common adjuvants are aluminum-based mineral salts (“alum”) which have been 
FDA-approved for several decades 98. Over the last decades, a few lipid-based adjuvants have 
been approved by regulatory agencies for seasonal and pandemic flu vaccines.  Highly-
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functional polymeric adjuvants are also being investigated and this is an area of application 
where PPZs have shown particular promise.  
Already in 1998, a polyanionic PPZ derivative, poly[di(carboxylatophenoxy)-phosphazene] 
(PCPP), was identified as a promising adjuvant for commercial influenza vaccines since it 
could significantly improve the immunogenic responses in mice around ten-fold in comparison 
with the antigen alone 99. It was found that the molecular weight of PCPP was also an important 
factor for boosting the immunogenic response. The longer PPZ (Mw 1500 kDa), when used as 
adjuvant for triple influenza vaccine, had 5 times higher hemagglutination inhibition antibodies 
than the same formulation prepared with the shorter PPZ (Mw 58 kDa). 
The mechanism behind the immunostimulatory properties of PCPP is still unclear, but several 
explanations have been suggested 100. First, PCPP does not seem to form a “depot” like alum 99, 
but rather moves out of the injection site as dispersed hydrophilic complexes carrying the 
antigen. Second, PCPP forms non-covalent complexes with antigens, and the resulting 
nanoparticle structure seems to promote protein stability and more efficient antigen 
presentation to immune cells. This molecular complex formation process is likely affected by 
the molecular weight of PCPP, since larger polymers result in larger nanocomplexes and those 
induce higher amount of serum IgG titers in mice 99. In addition, the carboxylic acid grafted 
groups on the PPZ backbone have inherent immunostimulatory activity, which could be 




Figure 5. The chemical structure of PCPP and PCEP, two PPZ-based adjuvant materials, and 
the different types of vaccine formulations derived from them. 
 
The use of PPZs as adjuvants is not only restricted to PCPP. Another PPZ with similar structure, 
poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP), can also boost immune 
responses in vaccination 103,104. PCEP has been tested as adjuvant with different antigens: BSA, 
X-31 influenza, and hepatitis B surface antigen (HBsAg). When compared to PCPP, it was 
observed that PCEP trigger higher total IgG titers in vivo after several weeks. More specifically, 
PCEP used as adjuvant with relative low doses of X-31 stimulated high IgG titers and induced 
higher interferon-γ production than alum or PCPP 104. Either alum or PCPP mixing with X31 
has a relatively high IgG1/IgG2a ratio of 1.3, indicating a predominantly Th2 type immune 
response in mice. In contrast, PCEP-adjuvant X31 has a, IgG1/IgG2a ratio of 0.9, presenting a 
balanced Th1/Th2 response with more Th1 isotype IgG2a. The reason behind this effect seems 
to be related to the different immunomodulatory effects of these adjuvants. While PCEP can 
contribute to stimulate both Type 1 T helper (Th1) and Type 2 T helper (Th2) responses, alum 
is mostly associated to Th2 responses. In fact, one of the main limitations of alum is its poor 
capacity to elicit Th1 responses, which is a main immune defense against intracellular 
pathogens.   
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Besides vaccine delivery by direct complexation with antigens, other PZZ systems have also 
been prepared, including nanocarriers (particles, liposomes) 105, microparticles 106-110, hydrogels 
111, and microneedle arrays 112 (Figure 5). A particularly promising approach is the use of 
viscous PCPP-coated microneedle arrays that can penetrate the skin and degrade once in the 
body, releasing the antigen and the adjuvant. Andrianov and co-workers developed a single 
dose vaccine of HBsAg based on PCPP-coated microneedles to be used via transdermal 
delivery. In studies performed in pigs, this delivery system produced around 10 times higher 
IgG titers than the same formulation administered by intramuscular injection 112. In summary, 
this study showed synergistic effects between the physical delivery exerted by the small 
needles and PPZs and demonstrated the potential of these material for minimally-invasive 
transdermal vaccination strategies. 
The first clinical trial on a PPZ-based adjuvant used PCPP co-administered with influenza 
antigens of three stains (A/Johannesburg/33/94 (H3N2)) in young adults and elderly 113. This 
phase I study confirmed no serious adverse effects for this formulation and achieved better 
immune responses in young subjects, although elderly subjects still benefited from higher 
seroconversion rate in the PCPP-adjuvant group than in the standard vaccine group.  
In addition to influenza, PCPP could be combined with HIV antigens to form macromolecular 
complexes. In vivo, PCPP-HIV Gag complexes activate more efficiently human dendritic cells 
(DCs) from adults and newborns and generate further cytokine production than the same 
antigen formulated with alum 114. PCPP complexed with HIV vaccine formulations (ALVAC-
HIV (vCP1521) primed with oligomeric gp160 (92TH023/LAI-DID) or Bivalent gp120 
(CM235/SF2) boost) were evaluated for immune responses and safety in clinical studies. The 
results of these studies indicated the safety of the vaccines and their capacity to induce cell-
mediated immunity 115,116. However, the protective effect of ALVAC-HIV (vCP1521) 
formulation was found to decay over time in these studies 117. Another prime-boost Phase I 
study reported the combinations of ALVAC-HIV (vCP205) with oligomeric glycoprotein 160 
(ogp160) and either PCPP or alum as adjuvants 118. The ogp160 subjects receiving the PCPP 
adjuvant had higher endpoint responses, including geometric mean antibody titers and T-Cell 
lympho-proliferation, than the subjects receiving the alum adjuvant (ClinicalTrials.gov 
Identifier NCT00004579).  
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In summary, for the moment the clinical evaluation has indicated that PPZ adjuvants are safe 
and immunostimulatory in humans, and that they can be translated to a variety of platforms 
including complexes, microparticles, gels, microneedles, etc. Further clinical studies are 
required to validate their utility for both influenza and HIV vaccination, particularly in 




Compared to other polymer families, stable PPZs have been synthesized relatively recently, and 
because of this and their anomalous inorganic backbone, they have not been explored as much 
as other biomaterials. Still, their many advantages have spurred increasing interest particularly 
concentrated in some areas like tissue engineering, gene delivery, protein delivery and 
vaccination. Particularly critical to this interest, is the biodegradability of most 
poly(organophosphazenes) and the chemical flexibility of these materials. Although other types 
of polymers can also be chemically diverse, engineers find appealing the special synthesis 
pathway of PPZs where a precursor is modified to tailor the material’s structure and meet the 
requirements of specific applications. Such synthesis route simplifies adapting existing 
technologies to new areas of interest. 
A pending challenge for the use of PPZs in pharmaceutics and medical devices is the 
optimization of this synthetic route to make it more cost-effective and eco-friendlier. Indeed, 
current synthetic pathways either rely on costly monomers and/or the use of high temperatures, 
organic solvents, and organic reactions proceeding under strict conditions. Cost considerations 
might be acceptable if the PPZ is integrated in large added-value systems where low amounts 
of material are needed (e.g. gene delivery systems) but can block further development in other 
applications.  
Regulatory considerations have also been a concern for the development of PPZ-based systems 
since these materials do not have a long history of medical record comparable to other 
polymers. In this regard, good biocompatibility data observed in several animal models 
suggests that many PPZs can be considered for clinical translation. This good biocompatibility 
profile has been confirmed by the first clinical trials conducted with 
poly[di(carboxylatophenoxy)-phosphazene]. It is expected that all this new data on safety and 
bioactivity will encourage new laboratories to consider PPZ as important materials for the 
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